PLX2853

DRUG3 trials

Conditions

Advanced MalignanciesDiffuse Large B Cell LymphomaEpithelial Ovarian CancerFollicular LymphomaGynecologic NeoplasmsHigh-risk Myelodysplastic Syndrome (MDS)Non-Hodgkin LymphomaOvarian Clear Cell Carcinoma

Phase 1

A Study of PLX2853 in Advanced Malignancies.

CompletedNCT03297424

Opna Bio LLCAdvanced Malignancies, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +5

Start: 2017-09-12End: 2021-06-07Updated: 2022-07-25

A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

CompletedNCT03787498

Opna Bio LLCHigh-risk Myelodysplastic Syndrome (MDS), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML)

Start: 2019-03-19End: 2021-06-30Updated: 2022-04-12

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

TerminatedNCT04493619

Opna Bio LLCEpithelial Ovarian Cancer, Gynecologic Neoplasms

Start: 2020-08-11End: 2022-04-25Updated: 2024-11-04

Cancer Research2023-04-143 citations

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Blood2021-11-055 citations

Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.

Journal of Clinical Oncology2021-05-204 citations

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Blood2020-11-042 citations

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Blood2019-11-134 citations

PLX2853

Sponsors

Conditions

Phase 1

Related Papers